Management of type 2 diabetes mellitus. Approaches to pathogenetic therapy
AbstractThis clinical case shows the positive effects of adding alogliptin (Vipidia®) to metformin monotherapy on carbohydrate metabolism, lipid profile and body composition, muscle-fat ratio without significant weight dynamics. Knowing the positive effects of GLP-1 on fat metabolism, it can be assumed that the appointment of gliptins has an effect on reducing body fat mass.
Keywords: type 2 diabetes mellitus, DPP-4inhibitors, gliptins, alogliptin, Vipidia, bioimpedance analysis, body fat mass
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
For citation: Ametov A.S., Pyanykh O.P., Depyui T.I. Management of type 2 diabetes mellitus. Approaches to pathogenetic therapy. // Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (4): 82–7. DOI: https://doi.org/10.33029/2304-9529-2020-9-4-82-87 (in Russian)
REFERENCES
1. WHO. Diabetes. WHO, 2017 [Electronic resource]. URL: https://www.who.int/news-room/fact-sheets/detail/diabetes (date of access July 31, 2019)
2. IDF Diabetes Atlas. 8th ed. 2017 (Electronic resource). URL: https://diabetesatlas.org/resources/2017-atlas.html (date of access July 31, 2019) (in Russian)
3. Shestakova M.V., Kachko V.A. ENTIRE: research of real clinical practice of alogliptin application in the treatment of patients with type 2 diabetes in the Russian Federation. Russkiy meditsinskiy zhurnal [Russian Medical Journal]. 2019; 8 (I): 3–10. (in Russian)
4. Clinical recommendations «Algorithms of specialized medical care for patients with diabetes mellitus». In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 9th ed. Moscow, 2019. DOI: https://doi.org/10.14341/DM20151S 1–112 (in Russian)
5. Mkrtumyan A.M. Alogliptin is an effective and safe inhibitor of dipeptidyl peptidase-4 in the treatment of patients with diabetes mellitus type 2. Farmateka [Pharmateca]. 2015; 5 (298): 20–7. (in Russian)
6. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369 (14): 1327–35. DOI: https://doi.org/10.1056/NEJMoa1305889